BRISTOL-MYERS INVESTING IN CADUS UP TO $45 MIL FOR SCREENING TECHNOLOGY
BRISTOL-MYERS INVESTING IN CADUS UP TO $45 MIL FOR SCREENING TECHNOLOGY based on yeast strains. Ac cording to New York City based Cadus Pharmaceutical, advantages of the yeast-based screening system include: isolating novel molecular targets for drug discovery; the ability to measure "the biological activity of a compound, not merely its binding capability"; and quick results, "easy automation and stable storage." A joint committee will supervise research at Cadus and at BMS research facilities in Princeton, NJ., Wallingford, Conn. and Seattle, Wash.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth